bluebird bio (NASDAQ:BLUE) had its price target hoisted by SunTrust Banks to $223.00 in a research report report published on Tuesday morning, The Fly reports. SunTrust Banks currently has a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on BLUE. Wells Fargo & Company reissued an outperform rating and set a $242.00 target price (up previously from $190.00) on shares of bluebird bio in a report on Tuesday. Leerink Swann reissued an outperform rating and set a $120.00 target price on shares of bluebird bio in a report on Saturday, September 30th. BMO Capital Markets set a $215.00 target price on bluebird bio and gave the stock a buy rating in a report on Monday. Jefferies Group raised bluebird bio from a hold rating to a buy rating and lifted their target price for the stock from $130.00 to $211.00 in a report on Monday. Finally, Canaccord Genuity assumed coverage on bluebird bio in a report on Tuesday, December 5th. They set a buy rating and a $202.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. bluebird bio presently has an average rating of Hold and a consensus target price of $157.45.

bluebird bio (BLUE) traded down $0.55 on Tuesday, hitting $184.35. The stock had a trading volume of 1,719,500 shares, compared to its average volume of 866,462. bluebird bio has a 12 month low of $60.95 and a 12 month high of $222.03.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. During the same period in the prior year, the business posted ($2.07) EPS. The firm’s quarterly revenue was up 397.4% compared to the same quarter last year. research analysts forecast that bluebird bio will post -6.72 EPS for the current fiscal year.

In other news, insider Jeffrey T. Walsh sold 9,900 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $216.54, for a total transaction of $2,143,746.00. Following the sale, the insider now directly owns 37,205 shares in the company, valued at $8,056,370.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Mark Vachon sold 7,000 shares of the business’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $216.64, for a total value of $1,516,480.00. Following the sale, the director now owns 8,000 shares in the company, valued at $1,733,120. The disclosure for this sale can be found here. In the last quarter, insiders sold 97,582 shares of company stock worth $15,597,932. Company insiders own 3.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. grew its holdings in shares of bluebird bio by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock worth $1,096,000 after purchasing an additional 27 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of bluebird bio by 1.7% during the second quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 53 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in shares of bluebird bio by 0.8% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock worth $1,885,000 after purchasing an additional 140 shares during the last quarter. Prudential Financial Inc. grew its holdings in shares of bluebird bio by 4.0% during the second quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock worth $408,000 after purchasing an additional 150 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of bluebird bio by 0.5% during the second quarter. The Manufacturers Life Insurance Company now owns 31,433 shares of the biotechnology company’s stock worth $3,302,000 after purchasing an additional 151 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/bluebird-bio-blue-price-target-raised-to-223-00/1766123.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

The Fly

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with Analyst Ratings Network's FREE daily email newsletter.